Icon Pharma

Icon Therapeutics is a privately held biotechnology company pioneering the development of small molecule medicines that target "pioneer" transcription factors. The company utilizes a specialized platform combining single-molecule tracking (SMT) and high-resolution live-cell imaging to observe protein-DNA interactions in real-time within living cells. This technology enables the identification of novel binding sites and mechanisms for drugging transcription factors that were previously considered "undruggable." With a significant $512 million Series A/B funding round in 2024, Icon is advancing a pipeline focused on oncology and neurodegenerative diseases, aiming to reset gene expression patterns driven by disease-causing transcription factors.